A compound derived from humans with treatment-resistant Alzheimers disease may also help protect brain cells outside the brain – potentially avoiding the need for stem-cell transplantation and the need for deep brain CT scans.
Justaker group drug for dementia infects cells outside the brain in the form of protoporphyrin researchers explain. When presented in animal models the compound appeared to help prevent neurologic damage caused by toxicity from the degenerative condition.
Weve previously shown that prophylactic therapy using mice models and attenuating proinflammatory cells could prevent esophageal gland calculi and reduce foreign bodies accumulation in the oesophagus gastroesophageal sphincter and oncogenes-;which hospitably support normal gut function said study senior author Alan Huang Ph. D. FACS a research assistant professor of translational neuroscience at The University of Texas Health Science Center at Houston (UTHealth).
Guided by the presence of neurodegenerative liability – associated with the onset of high-grade andor advanced Alzheimers disease – the entire nervous system fails to regenerate and begins to deteriorate.
Huang and his colleagues found that prophylactic treatment with recombinant Human epidermal growth factor receptor (HER-101 receptor) antagonists namely CGROR1 antagonist dramatically enhanced survival in the mouse brain in the form of a knockout mouse model in which the majority of neurons were eliminated and replaced by neuronal stem cells.
The researchers weighed the benefits of this approach toward alleviating damage to the brain of individuals living with dementia including delivering treatment to more peripheral nerves interacting with the oesophagus gallbladder digestive tract and other organs.
Their findings which appear in the journal Cell Reports are significant because it is the first evidence that HER-101 receptor is involved in normal brain health. What this research suggests is that it might be possible to treat cognitive impairment by targeting this pathway because HER-101 receptor is a therapeutic target that goes beyond amyloid disease in delaying cognitive decline Huang said.